Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 8/20 | 0.38 |
| ▸ | CETP | P11597 | 5/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074811 | 1.00 | CYP3A4 (0.38) | CYP3A4HTTTACR1CETPCXCR3 | |
| SCHEMBL581857 | 1.00 | CYP3A4 (0.38) | CYP3A4HTTTACR1CETPCXCR3 | |
| SCHEMBL581176 | 0.92 | CHRM1 (0.38) | HTTTACR1ALDH1A1MAPTTDP1 | |
| SCHEMBL3069035 | 0.92 | CHRM1 (0.38) | HTTTACR1ALDH1A1MAPTTDP1 | |
| SCHEMBL3085316 | 0.92 | CHRM1 (0.38) | HTTTACR1ALDH1A1MAPTTDP1 | |
| SCHEMBL582055 | 0.88 | ALDH1A1 (0.45) | HTTTACR1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL581695 | 0.88 | ALDH1A1 (0.45) | HTTTACR1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3075286 | 0.88 | ALDH1A1 (0.45) | HTTTACR1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3074992 | 0.87 | PPARG (0.43) | CYP3A4TACR1CETPALDH1A1MAPT | |
| SCHEMBL582387 | 0.87 | PPARG (0.43) | CYP3A4TACR1CETPALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | CYP3A4 21/4885HTT 2375/4885TACR1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.